Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and overexpression of platelet-derived growth factor-B in papillary thyroid cancer

Endocrine-Related Cancer

Volumn 15, Issue 1, 2008, Pages 183-190

  Wang, Yangang ^a,b   Ji, Meiju ^a   Wang, Wei ^b   Miao, Zhimin ^b   Hou, Peng ^a   Chen, Xinyan ^b   Xu, Feng ^b   Zhu, Guangwu ^b   Sun, Xianlu ^b   Li, Yujun ^b   Condouris, Steven ^a   Liu, Dingxie ^a   Yan, Shengli ^b   Pan, Jie ^b   Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PLATELET DERIVED GROWTH FACTOR B;

ADULT; ADVANCED CANCER; ARTICLE; CANCER INVASION; CANCER STAGING; CHINESE; COHORT ANALYSIS; DNA SEQUENCE; ECTOPIC THYROID GLAND; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HEMATOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PAPILLARY THYROID CANCER; PATHOGENESIS; PATHOLOGY; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; T1799A GENE; THROMBOCYTE COUNT; THYROID CANCER; TUMOR GENE;

ADENOCARCINOMA, PAPILLARY; ADULT; CHINA; COHORT STUDIES; DISEASE PROGRESSION; DNA PRIMERS; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; PLATELET COUNT; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-SIS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS;

EID: 41349086666     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0182     Document Type: Article

References (34)

1. Adeniran AJ, Zhu Z, Gandhi MC, Steward DL, Fidler JP, Giordano TJ, Biddinger PW & Nikiforov YE 2006 Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. American Journal of Surgical Pathology 30 216-222.
2. Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guillé F & Patard JJ 2006 Prognostic value of thrombocytosis in renal cell carcinoma. Journal of Urology 175 859-863.
3. Brown KM, Domin C, Aranha GV, Yong S & Shoup M 2005 Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. American Journal of Surgery 189 278-282.
4. Davies L & Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association 295 2164-2167.
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W et al. 2002 Mutations of the BRAF gene in human cancer. Nature 417 949-954.
6. Fischer ANM, Fuchs E, Mikula M, Huber H, Beug H & Mikulits W 2007 PDGF essentially links TGF-β signaling to nuclear β-catenin accumulation in hepatocellular carcinoma progression. Oncogene 26 3395-3405.
7. Frasca F, Nucera C, Belfiore A, Piero G, Attard M, Stella M, Pellegriti G, Giordano C, Trimarchi F & Vigneri R 2006 June 24-27 BRAF T1799A mutation in thyroid cancer predicts progressive disease. Abstract #OR 20-2, the 88th Endocrine Society Annual Meeting, Boston, Massachusetts, USA.
8. Garnett MJ & Marais R 2004 Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6 313-319.
9. Hernandez E, Donohue KA, Anderson LL, Heller PB & Stehman FB 2000 The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecological Oncology 78 137-142.
10. Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ, Tolaney S et al. 2006 Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. International Journal of Cancer 119 2322-2329.
11. Hundahl SA, Fleming ID, Fremgen AM & Menck HR 1998 A National Cancer Data Base report on 53 856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 83 2638-2648.
12. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M & Satomi T 2002 Poor prognosis associated with thrombocytosis in patients with gastric cancer. Annals of Surgical Oncology 9 287-291.
13. Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, SuI JY, Kweon GR, Ro HK et al. 2006 Influence of the BRAF V600E mutation on expression of VEGF in papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 91 3667-3670.
14. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SC & Shong YK 2006 The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clinical Endocrinology 65 364-368.
15. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE & Fagin JA 2005 Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Research 65 4238-4245.
16. Lee JH, Lee ES, Kim YS, Won NH & Chae YS 2006 BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology 38 201-204.
17. Liu S, Semenciw R, Ugnat AM & Mao Y 2001 Increasing thyroid cancer incidence in Canada 1970-1996: time trends and age-period-cohort effects. British Journal of Cancer 85 1335-1339.
18. Mazzaferri EL 2006 An overview of the management of thyroid cancer. In Practical Management of Thyroid Cancer: A Multidisciplinary Approach, pp 1-28. Eds EL Mazzaferri, C Harmer, UK Mallick & P Kendall-Taylor. London, England: Springer-Verlag.
19. Mazzaferri EL & Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine 97 418-428.
20. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M et al. 2005 The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation 115 1068-1081.
21. Mesa C, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF & Fagin JA 2006 Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodelling. Cancer Research 66 6521-6529.
22. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T & Yamashita S 2003 Clinical implication of hot spot BRAF V599E, in papillary thyroid cancers. Journal of Clinical Endocrinology and Metabolism 88 4393-4397.
23. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A et al. 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 88 5399-5404.
24. Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K et al. 2006 BRAFV600E promotes invasiveness of thyroid cancer cells through NF-κ B activation. Endocrinology 147 5699-5707.
25. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A & Anand-Apte B 2003 A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nature Medicine 9 407-415.
26. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M & Santisteban P 2006 The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocrine-Related Cancer 13 257-269.
27. Salven P, Orpana A & Joensuu H 1999 Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clinical Cancer Research 5 487-491.
28. Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scélo G, Pukkala E, Hemminki K, Anderson A, Tracey E, Friis S et al. 2006 Second primary cancers in thyroid cancer patients: a multinational record linkage study. Journal of Clinical Endocrinology and Metabolism 91 1819-1825.
29. Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H, Takeda A, Gunji Y & Ochiai T 2004 Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. Journal of the American College of Surgeons 198 737-741.
30. Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A et al. 2007 Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. PNAS 104 2803-2808.
31. Verheul HM & Pinedo HM 2003 The importance of platelet counts and their contents in cancer. Clinical Cancer Research 9 3219-3221.
32. Xing M 2005 BRAF mutation in thyroid cancer. Endocrine-Related Cancer 12 245-262.
33. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine Reviews 28 742-762.
34. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G et al. 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 90 6373-6379.